PartnershipApr 9, 2026, 06:11 AM
IDEAYA Biosciences Enters Clinical Collaboration with AstraZeneca for IDE849 in Extensive-Stage SCLC
AI Summary
IDEAYA Biosciences, Inc. has announced a clinical collaboration agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849, IDEAYA's investigational DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca's Imfinzi® (durvalumab). This partnership targets extensive-stage small cell lung cancer (SCLC), an area with significant unmet medical need. IDEAYA will sponsor the clinical combination study, while AstraZeneca will supply Imfinzi®, highlighting a strategic alliance to advance this potential therapeutic option. The collaboration builds upon IDEAYA's ongoing global Phase 1 clinical trial for IDE849 across various DLL3-upregulated solid tumor indications.
Key Highlights
- IDEAYA Biosciences entered into a clinical collaboration agreement with AstraZeneca plc on April 8, 2026.
- The collaboration focuses on evaluating IDE849, IDEAYA's investigational DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca's Imfinzi® (durvalumab).
- The primary indication for the combination study is extensive-stage small cell lung cancer (SCLC).
- IDEAYA Biosciences will sponsor the clinical combination study, and AstraZeneca will supply Imfinzi®.
- IDE849 is currently in a multi-site global Phase 1 clinical trial for DLL3 upregulated solid tumor indications, including SCLC, neuroendocrine carcinomas (NECs), neuroendocrine tumors (NETs), and melanoma.
- The global Phase 1 study for IDE849 is enrolling patients across North America, Europe, Australia, South America, and Asia.